Skip Standard Navigation Links
Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z
peer-reviewed.gif (582 bytes)
eid_header.gif (2942 bytes)
 EID Home | Ahead of Print | Past Issues | EID Search | Contact Us | Announcements | Suggested Citation | Submit Manuscript

Volume 12, Number 6, June 2006

Antiretroviral Drug Resistance and Routine Therapy, Cameroon

Christian Laurent,* Charles Kouanfack,† Laurence Vergne,* Michèle Tardy,† Léopold Zekeng,‡§ Nathalie Noumsi,† Christelle Butel,* Anke Bourgeois,* Eitel Mpoudi-Ngolé,¶ Sinata Koulla-Shiro,† Martine Peeters,* and Eric Delaporte*
*Institut de Recherche pour le Développement (UMR 145), Montpellier, France; †Central Hospital, Yaoundé, Cameroon; ‡Laboratoire de Santé et d'Hygiène Mobile, Yaoundé, Cameroon; §National AIDS Program, Yaoundé, Cameroon; and ¶Military Hospital, Yaoundé, Cameroon

 
 
Figure.
  Back to article
 

Figure. Patients with resistance to antiretroviral drugs. NFV, nelfinavir; ATV, atazanavir; RTV, ritonavir; IDV, indinavir; PIs, protease inhibitors; NVP, nevirapine; EFV, efavirenz; non-NRTIs, non-nucleoside reverse transcriptase inhibitors; ABC, abacavir; ddC, zalcitabine; ddI, didanosine; TDF, tenofovir; d4T, stavudine; ZDV, zidovudine; FTC, emtricitabine; 3TC, lamivudine; NRTIs, nucleoside reverse transcriptase inhibitors.

 

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed May 4, 2006

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention